Overall and Intracranial Response
LORBRENA demonstrated a 48% overall ORR and an intracranial response in more than half of the patients (60%) with brain metastases

Overall ORR Chart

Overall ORR Chart

*Per Independent Central Review (ICR).

Intracranial ORR and duration of response were assessed per ICR in a subgroup of 89 patients with measurable baseline lesions in the CNS according to RECIST version 1.1. Of these, 56 (63%) patients received prior brain radiation, including 42 patients (47%) who completed brain radiation treatment at least 6 months before starting treatment with LORBRENA.

CNS=central nervous system; NR=not reached; ORR=overall response rate; RECIST=Response Evaluation Criteria in Solid Tumors.
Exploratory Analyses Were Conducted in Subgroups Defined by Prior Therapy

With or without prior chemotherapy.

§As their only ALK inhibitor.

Alectinib, ceritinib, or brigatinib, with or without prior chemotherapy.1